Keywords: Bristol-Myers Squibb, Financial results, Second quarter 2012

Patent expiries batter Bristol-Myers 2nd-quarter 2012 results

Article | 26 July 2012

Bristol-Myers Squibb (NYSE: BMY) posted second quarter 2012, highlighted by the planned $5.3 billion acquisition of Amylin Pharmaceuticals (The Pharma Letter July 2), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Go to company listing